Research programme: gamma interferon based therapeutics - A5 laboratories

Drug Profile

Research programme: gamma interferon based therapeutics - A5 laboratories

Alternative Names: VI-1718

Latest Information Update: 11 Mar 2011

Price : $50

At a glance

  • Originator A5 Laboratories
  • Class Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer; Multiple sclerosis; Viral infections

Most Recent Events

  • 11 Mar 2011 Preclinical development is ongoing in Canada
  • 28 Jul 2010 Preclinical trials in Viral infections in Canada (unspecified route)
  • 28 Jul 2010 Preclinical trials in Multiple sclerosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top